New data, published in Nature, advances our understanding of genetic mutations and their role in cancer development

Ambry Genetics Data Supports Functional Study of BRCA2, Helping Improve Variant Classification for Hereditary BRCA2-Linked Cancers

For Ambry Genetics
gwen@gwengordonpr.com

Ambry Genetics, a leader in clinical genomic testing, today announced its contribution to a study published in Nature that significantly advances our understanding of BRCA2 gene variants. As the uptake of genetic testing continues to grow, the need for scalable interpretation of the vast number of variants detected has become critical. This study was designed to leverage CRISPR/cas-9 gene editing to aid in the functional characterization of nearly 7,000 BRCA2 variants, helping to resolve variants of uncertain significance (VUS) and guide better clinical management.

BRCA2 is a well-established and clinically actionable gene associated with cancer predisposition.¹ Testing BRCA2 has long been a staple of hereditary cancer testing, as pathogenic variants in the gene are associated with cancers of the breast, ovary, prostate, and pancreas.^2-5 Despite the well-understood importance of BRCA2, at the time of this research, more than 5,000 BRCA2 variants are categorized as VUS in the National Institute of Health’s (NIH) ClinVar database (a catalogue of genomic variants and their classifications). Many of these are classified as VUS because there has been insufficient evidence to their classification.⁶

The study, led by Fergus J. Couch, PhD, of Mayo Clinic, brought together an interdisciplinary team of researchers from Mayo Clinic, H. Lee Moffitt Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Hospital Clinico San Carlos, Memorial Sloan Kettering Cancer Center, and Duke University, as well as Ambry Genetics, to understand and evaluate BRCA2 variants for their functional contributions to cancer pathogenesis.

The results of this study were integrated into a ClinGen/ACMG/AMP model for clinical interpretation, resulting in a 91% rate of classification showing the promise for improving the future of hereditary cancer testing results across all test providers.

“These findings illustrate the power of integrating functional genetic data with clinical analysis to improve understanding of hereditary cancer risk and optimize clinical management approaches,” said Marcy Richardson, PhD, Associate Director of Clinical Research at Ambry Genetics. “Functional testing of cancer-associated genes enables the clinical community to offer patients better data-informed recommendations on how best to mitigate cancer risk.”

“These findings demonstrate the value of collaborative research in advancing our understanding of BRCA2 variants, improving classification methods that support more accurate risk assessments and informed clinical care,” said Fergus Couch, Ph.D., Professor at Mayo Clinic and lead author of the study. “By integrating functional studies with clinical data, we can provide clinicians with valuable tools to guide patients in managing their hereditary cancer risks.”

“Genetic testing and variant analysis are paving the way towards truly personalized clinical care for patients before they have cancer, moving us well beyond the time when clinical decision-making based on family history left many clinicians and patients feeling powerless to intervene prior to cancer onset,” said Elizabeth Chao, MD, FACMG, Chief Medical Officer at Ambry Genetics. “Improving the quality of data available in our genetic databases allows us to better classify variants across diverse populations, offering a more inclusive approach to genetic testing, giving clinicians new tools for recommending measures to prevent cancer.”

This paper is co-published alongside another related study with the NIH, which examines the same issues using a different model. Together, these studies represent a major step forward in variant classification, providing essential data that helps clinicians better assess cancer risks tied to genetic mutations.

For more information about Ambry Genetics’ solutions for hereditary cancer testing, visit www.ambrygen.com/providers/oncology.

About Ambry Genetics

Ambry Genetics translates scientific research into clinically actionable test results based upon a deep understanding of the human genome and the biology behind genetic disease. It is a leader in genetic testing that aims to improve health by understanding the relationship between genetics and disease. Its unparalleled track record of discoveries over 25 years, and growing database that continues to expand in collaboration with academic, corporate, and pharmaceutical partners, means Ambry Genetics is first to market with innovative products and comprehensive analysis that enable clinicians to confidently inform patient health decisions.

_____________________________

¹ Tavtigian, S. V. et al. The complete BRCA2 gene and mutations in chromosome 13q- linked kindreds. Nat Genet 12, 333-337, doi:10.1038/ng0396-333 (1996).
² Hu, C. et al. A Population-Based Study of Genes Previously Implicated in Breast Cancer. N Engl J Med 384, 440-451, doi:10.1056/NEJMoa2005936 (2021).
³ Kotsopoulos, J. et al. Germline Mutations in 12 Genes and Risk of Ovarian Cancer in Three Population-Based Cohorts. Cancer Epidemiol Biomarkers Prev 32, 1402-1410, doi:10.1158/1055-9965.Epi-23-0041 (2023).
⁴ Agalliu, I. et al. Germline mutations in the BRCA2 gene and susceptibility to hereditary prostate cancer. Clin Cancer Res 13, 839-843, doi:10.1158/1078-0432.Ccr-06-2164 (2007).
⁵ Hu, C. et al. Association Between Inherited Germline Mutations in Cancer Predisposition Genes and Risk of Pancreatic Cancer. JAMA 319, 2401-2409, doi:10.1001/jama.2018.6228 (2018).
⁶ Landrum, M. J. et al. ClinVar: improving access to variant interpretations and supporting evidence. Nucleic Acids Res 46, D1062-d1067, doi:10.1093/nar/gkx1153 (2018).

View source version on businesswire.com: https://www.businesswire.com/news/home/20250108118368/en/